康恩贝：2021年至2024年累计研发投入11.2亿元

Core Viewpoint - The company, Kang En Bei, has significantly increased its R&D investment and is focusing on innovative drug development, which is expected to drive future growth and enhance company value [1] R&D Investment and Financial Performance - From 2021 to 2024, the company plans to invest a total of 1.12 billion yuan in R&D, with R&D expenses rising from 3.5% to 5% of revenue [1] - The company has achieved a compound annual growth rate (CAGR) of 2% in operating revenue and 48% in net profit attributable to the parent company from 2021 to 2024 [1] - Net assets increased from 5.03 billion yuan at the beginning of 2021 to 7.061 billion yuan by the end of Q3 2025 [1] Drug Development and Approvals - The company has received approvals for three innovative drugs and one traditional Chinese medicine formulation [1] - Multiple innovative development projects are progressing towards key milestones, including EVT-401 and a traditional Chinese medicine oral liquid, which have entered Phase II clinical trials [1] Shareholder Value Enhancement - The company has repurchased a total of 161 million shares between November 2021 and July 2025 [1] - The company is actively implementing measures such as major shareholder buybacks, company repurchases, and cash dividends to maintain and enhance its value [1] Strategic Direction - The company is focusing on strategic opportunities in the traditional Chinese medicine health sector and is actively seeking potential acquisition targets that align with its strategic direction [1]